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Background: The aim of this study was to clarify the clinicopathological outcome of serum relaxin-2 and tissues
relaxin-2 expression levels in human primary osteosarcoma (OS), and to explore the roles of relaxin-2 inhibition and
determine its possibility as a therapeutic target in human osteosarcoma.
Methods: Real-time quantitative RT-PCR assay was performed to detect the expression of relaxin-2 mRNA in 36
cases of human osteosarcoma tissue samples. Serum relaxin-2 levels was measured in ELISA-based method in the
36 cases of osteosarcoma and 50 cases of controls. MTT and TUNEL assay was used to detect cell proliferation and
apoptosis after relaxin-2 knockdown with siRNA transfection for 48 hs in vitro. Matrigel invasion and angiogenesis
formation assay was used to detect cell metastasis and angiogenesis with HMEC-1 endothelial cells after relaxin-2
knockdown with siRNA transfection for 48 hs in vitro. The effects of relaxin-2 knockdown with anti- relaxin-2 mAb
treatment on growth, apoptosis angiogenesis formation and lung metastasis in vivo was analyzed.
Results: The results showed the levels of relaxin-2 mRNA expression in osteosarcoma tissue samples were
significantly higher than those in the corresponding non-tumor tissue samples (P < 0.01), and the serum relaxin-2
levels were significantly higher in OS patients than in healthy controls (P < 0.01). The incidence of advanced stage
cancer and hematogenous metastasis cancer in the high relaxin-2 mRNA expression group and high serum
relaxin-2 levels groups was significantly higher than that in the low relaxin-2 expression group and low serum
relaxin-2 levels groups, respectively. Knockdown of relaxin-2 by siRNA transfection in vitro inhibited proliferation,
invasion and angiogenesis in vitro in MG-63 OS cells. In vivo, knockdown of relaxin-2 with anti- relaxin-2 mAb
treatment inhibited tumor growth by 62% (P < 0.01) and the formation of lung metastases was inhibited by 72.4%
(P < 0.01). Microvascular density was reduced more than 60% due to anti- relaxin-2 mAb treatment (P < 0.01).
Conclusions: Our study suggests that overexpression of relaxin-2 is critical for the metastasis of human
osteosarcoma. Detection of relaxin-2 mRNA expression or serum relaxin-2 levels may provide the first biological
prognostic marker for OS. Furthermore, relaxin-2 is the potential molecular target for osteosarcoma therapy.
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One of the most common primary bone tumors in
children and adolescents is osteosarcoma, which is most
often localized in the metaphysis of the adolescent long
bones [1]. Similar to other types of solid tumors, osteosar-
coma is characterized by a high propensity for metastasis,
especially in lung, which is the main cause of death [2].
Standard treatment for osteosarcoma is surgery and
neoadjuvant chemotherapy [3]. Chemotherapy has sig-
nificantly improved the survival rate from 11% with
surgery alone to 60–70% when surgery is combined with* Correspondence: qyfymjf@126.com
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reproduction in any medium, provided the orchemotherapy [3,4]. Patients with advanced osteosar-
coma after front-line chemotherapy usually receive fur-
ther treatment with additional chemotherapy, which
may be considered toxic [5]. Unfortunately, not much
progress has been made on improving survival over the
past 20 years with regard to the treatment of osteosar-
coma. Thus, identification of new targeted therapies is a
crucial step forward in the drive towards personalized
medicine [3,5,6].
Relaxin is a short circulating peptide hormone. Two
highly homologous genes on human chromosome 9 en-
code relaxin −1 and relaxin −2 peptides with predicted
82% identity at amino acid level [7,8]. Despite having. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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major stored and circulatory form of relaxin in humans
is relaxin-2. relaxin-2 is produced in the prostate by
males [9] and corpus lutea in females [10], and relaxin-1
is a pseudogene, which does not translate into a func-
tional peptide in rodents, humans and other non-human
species.
The effect of relaxin, particularly during pregnancy, is
well established in rodents. Levels of relaxin-2 change
with the different stages of pregnancy and these patterns
are dissimilar across species [11]. Furthermore, relaxin-2
has been shown to increase oocytes fertility [12].
Relaxin-2 has also been shown to be involved in
nonreproductive functions [13]. Most recently relaxin-2
has been associated with cancer biology. A number of pu-
tative roles, including the modulation of tumor growth,
neovascularization, metastasis and oncogenic progression,
have been correlated to relaxin overexpression [9,14-16].
Elevated relaxin-2 serum concentrations were found in
breast cancer patients, especially in patients with meta-
static disease [17]. Stimulation with relaxin-2 increases
the invasiveness and migration of breast, endometrial,
and thyroid adenocarcinoma cells in vitro accompanied
by the up-regulation of matrix metalloproteinase activity
and vascular endothelial growth factor expression, which
are directly related to cancer progression [18-20].
It has recently found relaxin is able alone to induce
the differentiation of PBMCs into mature osteoclasts,
suggesting relaxin has an effect on bone metabolism,
facilitating the differentiation of osteoclasts [21,22]. Fur-
ther study showed that relaxin is a potent stimulator of
osteoclastogenesis from hematopoietic precursors and
regulates the activity of mature osteoclasts, which
opened new perspectives on the role of this hormone in
bone physiology, diseases and metastasis [22].
The aim of this study was to investigate the relaxin −2
expression in 36 cases of osteosarcoma tissues, and ana-
lyzed the association between clinical parameters of osteo-
sarcoma and relaxin −2 expression. Moreover, we address
the fundamental question of whether relaxin −2 down-
regulation is involved in reducing invasion and metastasis
in osteosarcoma cells and inhibition of tumorigenesis.
In the present study, we found that relaxin −2 mRNA
was overexpressed in osteosarcoma tissues, and high
serum relaxin −2 levels was in osteosarcoma patients.
Relaxin-2 mRNA and serum relaxin-2 were significantly
higher in advanced stage cancer and hematogenous me-
tastasis cancer. Exogenous down regulation of relaxin-2
suppressed proliferation angiogenesis and migration in
MG-63 cells and decreased tumor formation, metastasis
and angiogenesis in nude mice. Our study suggests that
aberrant expression of relaxin-2 is critical for the develop-
ment of human osteosarcoma, and relaxin-2 is the better
target gene for treatment of osteosarcoma.Methods
Patients and tissue samples
The study was approved by the Research Ethics Com-
mittee of Ministry of Public Health of China. Informed
consent was obtained from all of the patients. All speci-
mens were handled and made anonymous according to
the ethical and legal standards. A total of 36 primary
osteosarcoma and corresponding non-tumor tissue sam-
ples from the same specimens were collected from the
Department of Orthopaedics, the Affiliated Hospital of
Medical college, Qingdao university between Jan. 12 - 2006
and Oct. 26 - 2011. None of the patients had received
chemotherapy or radiotherapy before surgery. Closed
biopsies of all patients were performed by fine-needle
aspiration or trephine for diagnosis or/and then surgical
treatment. The biopsy samples with bone tissue were
decalcified. The pathological diagnosis was performed by
the same group of two senior pathologists experienced in
osteosarcoma diagnosis. Tumor size data were available
based on a review of the imaging studies and the pathology
reports. Tumor volume was calculated on the basis of an
ellipsoid formula, using the measurements: height × width ×
depth × 0.52. Patient characteristics were detailed in
Table 1. Samples were snap-frozen in liquid nitrogen and
stored at −80°C after they were resected.
ELISA-based measurement of serum relaxin-2
Concentrations of relaxin-2 in serum samples of 36
patients and 50 healthy individuals with equivalent distri-
bution of age and sex were determined using relaxin-2-
specific enzyme-linked immunosorbent assay kit (ELISA,
yfswbio, Shanghai, China) according to the manufacturer’s
protocol. Briefly, the sera were added in duplicate to the
wells of the microtiter plate coated with an antibody
against relaxin-2 with horseradish peroxidase-conjugate.
Then, absorbance at the wave length of 450 nm in each
microwell was measured using a Victor3 1420 Multilabel
Counter reader (Perkin-Elmer LAS GmbH, Rodgau,
Germany). Amounts of relaxin-2 were calculated using
standards included in the ELISA kit and software supplied
with Victor3. The lower limit of quantification was 0.1 ug/l
serum sample. The inter-and intraassay coefficients of
variation was 15 and 10.5% respectively.
RNA preparation and quantitative RT-PCR assay
Total RNA was extracted using Trizol (GIBCO/BRL),
and mRNA was isolated from total RNA by the
FastTrack mRNA isolation kit (Invitrogen). RNAs were
quantified by UV absorption measurements and stored
at −80°C. Isolated RNA was reverse transcribed into
cDNA using the Takara RNA PCR Kit (AMV) Ver.2
(Takara, Ohtsu, Japan) according to manufacturer’s in-
structions. Real-time quantitative PCR was done using
the ABI Prism 7700 Sequence Detection System (Perkin-
Table 1 Association between relaxin-2 mRNA expression and clinicopathologic factors
Clinicopathologic factor Total Serum relaxin-2 Relaxin-2 mRNA expression
(mean ± SEM) (ng/mL) P-Value Low(n) High(n) P-Value
Sex 0.456 0.568
Female 20 88.24 ± 13.27 7 13
Male 16 91.58 ± 12.36 8 8
Age(Years) 0.087 0.092
<20 21 95.23 ± 14.16 6 15
≥20 15 83.62 ± 12.61 9 6
Tumor location 0.562 0.67
Extremity 14 91.54 ± 15.13 6 8
Axial 22 89.67 ± 14.86 9 13
Histologic subtypes 0.893 0.746
Osteoblastic 12 91.65 ± 13.02 5 7
Chondroblastic 10 90.54 ± 13.48 4 6
Fibroblastic 9 89.04 ± 14.23 3 6
Telangiectactic 5 91.86 ± 13.35 3 2
Clinical stage 0.004 0.018
I + II 20 76. 4 ± 15.27 11 9
III 16 114.53 ± 17.26 4 12
Hematogenous metastasis 0.001 0.002
No 15 70.53 ± 10.42 11 4
Yes 21 108.6 ± 14.87 4 17
Grade 0.742
High 30 89.12 ± 13.90 0.642 11 19
Moderate 3 94.40 ± 12.16 2 1
Low 3 96.18 ± 12.45 2 1
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contained 1 μl of cDNA, TaqMan Universal PCR master
mix (Perkin-Elmer Applied Biosystems), primer pair, and
TaqMan probe in a final volume of 50 μl. The PCR
conditions were an initial denaturation step of 2 min at
50°C and 10 min at 95°C, followed by 33 cycles
consisting of 15 s at 95°C, and a 1 min at 60°C. Quanti-
tative normalization of Relaxin-2 cDNA in each sample
was done using β-actin as an internal control. Real-time
PCR assays were done in triplicate, and the mean values
were used for calculations of mRNA expression. Equal
amounts of cDNA from each sample were amplified
using the following primers to detect the expression of
Relaxin-2: sense: 5′-TGCTGCGCTGGTTCTTGTCC′-3′,
reverse: 5′-ACCGTGTTGCTATCCTCAGTTCCT-3′ with
an expected size of 306 base pairs (bp). Quantitative
real-time RT-PCR assay was performed to detect β-
actin expression that was used to normalize the amount
of cDNA for each sample. β-actin primers were as
follows: sense: 5′-GTGCGTGACATTAAGGA-3′, reverse:
5′-CTAAGTCATAGTCCGCC-3′ (520 bp). Cut-off pointselection for the Relaxin-2 mRNA was performed by
searching for a cut point yielding the smallest log-rank
P-value and divided to the higher and lower Relaxin-2
mRNA expression levels.
Cell lines and reagents
The human osteosarcoma cell lines MG-63, U-2OS and
Saos-2 were obtained from the ATCC (Rockville, MD),
and incubated in RPMI 1640 medium containing 10%
fetal calf serum (FCS, Gibco) and 1% antibiotics (P/S,
penicillin 10.000 U/ml and streptomycin 10.000 mg/ml,
in 75 cm2 culture flasks (Falcon, Mountain View, CA)
until they had formed a confluent monolayer. Relaxin 2
siRNA (h) was acquired from Santa Cruz. MAb to
Relaxin 2 was from Biodesign (Shanghai, China).
Transfection with small interfering RNA (siRNA)
Relaxin-2 siRNA was acquired from Santa Cruz, Shanghai,
China. Cells (1 × 105 cells) MG-63 cells were maintained
in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum, penicillin
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fore transfection, cells were trypsinized and resuspended
in DMEM without antibiotics, and plated into a 24-well
plate at a density of 1.5 × 105 per 0.6 ml per well. Relaxin-2
siRNA was performed using Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer's protocol. A
control green-fuorescent protein (GFP) siRNA was as a
control. A 10 nM concentration of siRNA was used for
the transfections. 72-h after transfection, the cells were
harvested for western blot analysis of the knockdown level
of the exogenous proteins by siRNA.
Western blot analysis
Cells were harvested, pelleted by centrifugation, washed
with ice-cold PBS, and lysed with RIPA buffer (150 mM
NaCl, 50 mM Tris base pH 8.0, 1 mM EDTA, 0.5%
sodium deoxycholate, 1% NP-40, 0.1% sodium dodecyl
sulfate, 1 mM DTT, 1 mM PMSF, and 1 mM Na3VO4)
supplemented with protease inhibitor. Protein concentra-
tion of the supernatants of cell extract was determined
using a BCA protein assay kit (Pierce Biotechnology, Inc.).
Equal amounts of proteins were loaded on 10% SDS-
polyacrylamide gel. After electrophoresis, the proteins
were transferred to PVDF membranes, and the blots were
subsequently probed with the following antibodies:
Relaxin-2 (1:100) and anti-β-actin (C-2, used as a total
protein loading control)were all purchased from Santa
Cruz Biotechnology, Santa Cruz, CA, USA). For detection,
horseradish peroxidase-conjugated secondary antibodies
were used (1:500) followed by enhanced chemilumines-
cence development(Millipore). Normalization of the re-
sults was done by running parallel Western blots using
actin as control. The optical density was quantified using
an AlphaEase FC Version4 analysis software (Alphalmager
HP, Alpha Innotech, San Leandro, CA, USA).
Cell proliferation assay
The effect of Relaxin 2 sliencing on proliferation was dem-
onstrated using MTT assay. In brief, cells transfected with
relaxin 2 siRNA for 24 hours were seeded into 96-well
plates at 1 × 104 per well. After incubation for 24, 48, 72,
or 96 h, 200 uL of MTT reagent (5 mg/mL; Sigma) was
added to each well. Plates were incubated at 37°C for 4 h
and then the supernatant was removed and 200 uL of
dimethyl sulfoxide (Sigma) was used to dissolve the
resultant formazan crystals. The absorption was read
at 490 nm using a spectrophotometer. The MTT assay
was performed in triplicate.
Tunel staining
Cells transfected with relaxin 2 siRNA for 48 hs were
plated on polylysine-coated slides, fixed with 4% parafor-
maldehyde in 0.1 M phosphate-buffered saline (PBS) for
1 h at 25°C, rinsed with 0.1 M PBS, pH 7.4, andpermeabilized with 1% Triton X-100 in 0.01 M citrate
buffer, pH 6.0. DNA fragmentation was detected using
an ApopTag Kit (Chemicon international, Temecula, CA)
according to the manufacturer’s instructions. The per-
centage of apoptotic cells was calculated as the number of
apoptotic cells per number of total cells × 100%.
Matrigel invasion assay
The invasiveness of OS cells was tested after transfection
(48 hs) as previously described. The MG-63 cells (1 ×
106/mL) were added to the upper wells coated with
Matrigel with serum-free medium containing 25 ug/mL
fibronectin as a chemoattractive agent in the lower wells.
After a 24-h incubation period, cells that migrated
through the filters into the lower chamber were counted
by the number of cells on the lower side of the mem-
brane in five random fields after staining with Hema-3
kit.
In vitro angiogenesis assay
MG-63 cells (2 × 104/mL) were transfected with relaxin
2 siRNA for 48 h and the conditioned medium was
filtered off for future research. HMEC-1 endothelial cells
(4 × 104) were seeded onto eight-well chamber slides and
the aforementioned conditioned medium was added.
Cells were cultured for 72 h until capillary network for-
mation was observed. The number of branch points and
total number of branches per point were counted after
H&E staining to quantify the degree of angiogenesis
Animal studies
Male SCID mice, each 8 weeks old and weighing 20–25 g,
were obtained from Qingdao Medical college, Qingdao
University for tumor implantation. All animals were
maintained in a sterile environment and cared for
within the laboratory animal regulations of the Ministry
of Science and Technology of the People’s Republic of
China (http://www.most.gov.cn/kytj/kytjzcwj/200411).
Full details of the study approval by the ethics commit-
tee at the affiliated hospital of medical college, Qingdao
University. MG-63 cells were trypsinized, washed with
serumfree MEM, and resuspended in PBS, after which
their concentration was adjusted to 2 × 104 cells/100 uL
in PBS. To generate orthotopic xenograft models, these
cell suspensions were injected into the anterior tibialis
muscle of the SCID mice. After 24 h, these mice
received intraperitoneal injections of 100 uL of PBS
containing 100 ug of anti- relaxin-2 mAb (Cellmid Limited)
(n = 5) or PBS alone (n = 5); the mice received this same
treatment every 5 days for 42 days. Tumor development in
individual animals (n = 5/group) was assessed every 7 days
by means of sequential measurements of the bilateral differ-
ence in calf circumferences. Mice were killed 42 days after
injections of cells, and the tumors were harvested. For the
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transfected with Relaxin-2 siRNA were trypsinized,
washed, and resuspended in PBS, and their concentration
was adjusted to a concentration of 1 × 105 cells/100 uL in
PBS. MG-63 cell suspensions were then injected into the
tail vein of SCID mice, followed by analysis of settlement
of tumor cells to lung after 2 weeks. Micro-metastasis
were counted through the whole lung section on slides
using a microscope and quantified.
Microvessel density
The tumor vasculature was stained with an antibody
against CD31, and microvessel density (MVD) was de-
termined by counting CD31-stained vessels of tumor
slides by examining “hotspots” according to the manufac-
ture’s instruction. Vessel density per 200 field was quanti-
fied from 6 to 8 fields per tumor section from the
treatment and control groups and expressed as percentage
per area (200× field). Percentage per area was assessed
using ProImage software.
Statistical analysis
All experiments were conducted in triplicate and carried
out on three or more separate occasions. Data presentedFigure 1 Detection of relaxin-2 mRNA expression in tissue samples. A
Osteosarcoma tissues showed obviously higher relaxin-2 mRNA expression
for any differences in mRNA between lanes. Student’s t-test showed a signare means of the three or more independent experi-
ments ± SE. Statistically significant differences were
determined by X2 and Student’s t test and were defined
as *P < 0.05. All analyses were performed with SPSS
version 13.0 software.
Results
Overexpression of relaxin-2 mRNA in osteosarcoma tissue
samples
Real-time quantitative RT-PCR assay was performed to
detect the expression of relaxin-2 mRNA in osteosar-
coma tissues or corresponding non-tumor tissues from
36 osteosarcoma patients. As shown in Figure 1A, the
levels of relaxin-2 mRNA expression in osteosarcoma
tissue samples were significantly higher than those in
the corresponding non-tumor tissue samples, which
showed no or very low levels of relaxin-2 mRNA expres-
sion. Moreover, the average level of relaxin-2 mRNA
(0.743 ± 0.12) in tumor tissues was significantly higher
than that in corresponding non-tumor tissues (0.106 ±
0.06; Figure 1B, P < 0.01). Additionally, patients with
relaxin-2 mRNA expression levels in tumor tissues less
than 0.392 (average value) were considered as the low
expression group (n = 15), and patients with relaxin-2. Gel images of electrophoresis. B. Real-time quantitative RT-PCR assay.
than corresponding non-tumor tissues. β-actin was used to normalize
ificant difference (*P < 0.01).
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greater than 0.392 were considered as the high expression
group (n = 21).
Serum levels of relaxin-2
ELISA assay was performed to detect the serum
relaxin-2 levels in 36 osteosarcoma patients and 50
controls. In healthy donors, serum levels of relaxin-2
were 11.47 ± 3.24 ng/ml (mean ± SEM) ranging from
0.28 to 16.74. ng/ml. In OS patients, the corresponding
values were 90.37 ± 13.56 ng/ml (mean ± SEM) ranging
from 8.6 to 132.5 ng/ml. The serum relaxin-2 levels
were significantly higher in OS patients than in healthy
controls (P < 0.01).
The correlation between relaxin-2 mRNA or serum
relaxin-2 levels and clinical pathological stages
We evaluated the correlation between relaxin-2 mRNA
expressions in the OS tissues with clinical pathological
stages as shown in Table 1. The incidence of advanced
stage cancer in the high relaxin-2 mRNA expression
group (12 of 16, 75%) was significantly higher (P = 0.018)
than that in the low relaxin-2 expression group (9 of 20,
45%), and the incidence of hematogenous metastasis in
the high relaxin-2 mRNA expression group (17 of 21,
81%) was significantly higher (P = 0.002) than that in the
low relaxin-2 expression group (4 of 25, 16%). However,
there were no associations between relaxin-2 mRNA ex-
pression and other factors including gender, age, grade,
tumor location or histology (P = 0.568, 0.092, 0.549,
0.742 and 0.746, respectively). Similar to relaxin-2
mRNA, serum relaxin-2 were significantly higher in
advanced stage cancer and hematogenous metastasis
cancer (Table 1). There were no associations between
relaxin-2 levels and other factors including gender, age,
grade, tumor location or histology, respectively.
Expression of relaxin-2 in human osteosarcoma cell lines
Relaxin-2 protein and mRNA was examined in 3 human
osteosarcoma cell lines MG-63, U-2OS and Saos-2 by
western-blot and QRT-PCR. The results showed that the
MG-63 cell line had the highest expression level ofFigure 2 Detection of relaxin-2 mRNA and proterin expression in hum
B. Western blot assay. MG-63 cell line had the highest expression level of r
higher relaxin-2 mRNA expression than corresponding non-tumor tissues. β
between lanes.relaxin-2 mRNA (Figure 2A) and protein (Figure 2B).
U-2OS and Saos-2 cells displayed low expression levels.
In this regard, the cell line MG-63 was chosen for fur-
ther studies.
Down-regulation of relaxin-2 in human osteosarcoma
MG-63 cell line
The cell line MG-63 was transiently transfected with ei-
ther relaxin-2 siRNA or the control siRNA for 48 h, then
the cells were lysed and processed for mRNA and protein
analysis. Relaxin-2 siRNA transfectants showed a remark-
ably reduced expression of relaxin-2 mRNA (Figure 3A)
and protein (Figure 3B) levels. These observations pro-
vided direct evidence that relaxin-2 siRNA transfection
could effectly repressed relaxin-2 expression in human
osteosarcoma MG-63 cell lines.
Effect of relaxin-2 knockdown on osteosarcoma MG-63
cell proliferation and apoptosis
We next investigated the role of relaxin-2 in osteosar-
coma by means of relaxin-2 knockdown with siRNA. As
Figure 4A shows, relaxin-2 knockdown by siRNA for
48 hours inhibited MG-63 cell proliferation significantly
by MTT assay compared to MG-63-non-transfection or
MG-63-siRNA control cells respectively.
Apoptosis was quantified by TUNEL analysis. Follow-
ing relaxin-2 knockdown with siRNA for 48 hs, the
apoptotic MG-63 cells was 8.4%, more than that of MG-
63-non-transfection (1.2%) or MG-63-siRNA control
(1.3%) cells respectively, which showed significant differ-
ence in their apoptotic response (Figure 4B). The results
indicates that transfection might, to a large degree,
inhibit proliferation by inducing apoptosis in OS cells.
Effect of relaxin-2 knockdown on osteosarcoma MG-63
cell invasion
The result (Figure 5A) from Matrigel invasion assay in-
dicates that relaxin-2 knockdown with siRNA signifi-
cantly inhibited the invasion of MG-63 cells by 83%, as
compared with mock-transfected and MG-63-non-
transfected cells. Furthermore, the results (Figure 5B)
showed that HMECs treated with conditioned mediaan osteosarcoma cell lines. A. Gel images of electrophoresis.
elaxin-2 mRNA and protein. Osteosarcoma tissues showed obviously
-actin was used to normalize for any differences in mRNA
Figure 3 Effects of relaxin-2 mRNA on relaxin-2 mRNA and protein assessed by quantitative RT-PCR and western blot assays. Relaxin-2
mRNA (A) and protein (B) was completely inhibited by relaxin-2 siRNA transfection for 48 hs than those of MG-63-non-transfection or
MG-63-siRNA control cells respectively.
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capillary-like structures. It shows that HMECs treated
with conditioned media from relaxin-2 siRNA -transfected
MG-63cells showed less capillary-like networks (63%), as
compared with the controls.
Effect of relaxin-2 inhibition with anti- relaxin-2 mAb on
tumor growth in nude mice
Having shown that relaxin-2 knockdown with siRNA
decreased invasion and angiogenesis in MG-63 cells
in vitro, we tested the growth of the tumors accom-
plished by anti- relaxin-2 mAb on tumor growth in nude
mice. As shown in Figure 6A, the tumors MG-63 cells
treated with anti- relaxin-2 mAb for 42 d showed a sig-
nificant reduction of tumor volum as compared with
control groups, whereas MG-63 cells developed obvious
tumors in nude mice. Analyzing tissue sections from
tumors showed that anti- relaxin-2 mAb significantly in-
creased apoptosis in the tumors as assessed by TUNEL
staining (Figure 6B). Furthermore, we analyzed the
tumor tissues from control and anti- relaxin-2 mAb
groups for relaxin using Western blot assay. We
observed significant expression levels of relaxin-2 in
control tumor sections. However, expression levels were
drastically reduced in the tumor sections of mice treated
with anti- relaxin-2 mAb (data not shown). These data
show that relaxin-2 inhibition effectively inhibits the
growth of OS tumors through apoptosis induction.Figure 4 Effect of relaxin-2 knockdown on osteosarcoma MG-63 cell p
The growth rate of MG-63 cells after relaxin-2 knockdown with siRNA for 4
determined by TUNEL analysis in MG-63 cells following relaxin-2 knockdow
transfectants were significantly higher compared to MG-63-non-transfection
from triplicate experiments; Each bar represents mean ± SE (n = 3); *, P < 0.0Relaxin-2 inhibition with anti- relaxin-2 mAb decreased
MVD
To determine whether relaxin-2 blockade has an effect
on MG-63 tumor vasculature, MVD was analyzed. New
blood vessel formation was significantly reduced in MG-
63 tumor by anti- relaxin-2 mAb in the intervention
model (80% inhibition). The percentage area occupied
by vasculature in anti- relaxin-2 mAb–treated tumors
was 0.57 ± 0.22% versus 1.84 ± 0.26% in controls (n = 8;
P < 0.01; Figure 6C).
Relaxin-2 knockdown by siRNA diminished lung
metastasis
Mice with MG-63/ relaxin-2 siRNA cells were sacrificed
on the same day of tumor injection (14 days), lungs were
harvested and lung sections were examined for cancer
cell micrometastasis. The number of macroscopic tumor
nodules in relaxin-2 siRNA-treated mice was 9.46 ± 1.8
lung nodules per mouse versus 72.4 ± 7.4 nodules in the
controls (n = 5 mice/group). *, P < 0.01 (Figure 6D).
Discussion
In the present study, we found that the expression of
relaxin-2 mRNA were significantly higher in osteosarcoma
tissue samples than those in corresponding non-tumor tis-
sue samples. Moreover, the higher expression levels of
relaxin-2 mRNA were significantly correlated with clinical
stage and the status of hematogenous metastasis but notroliferation and apoptosis. A, Cell viability was determined by MTT.
8 hs was significantly decreased in MTT assay. B, Apoptotic cells was
n with siRNA for 48 hs. The apoptotic cells in relaxin-2 siRNA
or MG-63-siRNA control cells respectively. Columns, mean values
5 versus MG-63-non-transfection or MG-63-siRNA control.
Figure 5 Effect of relaxin-2 knockdown with siRNA on invasion and angiogenesis. A, invasiveness of MG-63 cells transfected with relaxin-2
siRNA in Matrigel invasion assay. Cells were transfected with mock siRNA or relaxin-2 siRNA. After 48 h, 1 × 105 cells were allowed to invade
through transwell inserts (8 Am) coated with Matrigel. The cells on lower surface of chambers were stained, counted, and photographed under a
light microscope. The in vitro inhibition of invasiveness was calculated in five random 200-fold fields using the following formula: percent
inhibition = (mock siRNA-relaxin-2 siRNA) /mock. Columns, mean from three separate experiments; bars, (*P < 0.01). B, HMEC endothelial cells
treated with conditional medium from MG-63 cells after siRNA transfection by in vitro angiogenesis assay. The conditioned medium of MG-63
cells was collected after 48-h transfection following filtering of medium. HMEC-1endothelial cells seeded in eight-chamber slides were cultured
with the above medium for 72 h until the formation of capillary network was observed. In the end of the experiment, angiogenesis was assessed
by H&E staining and photographed under a microscope. columns, mean from three separate experiments; bars, SD (*P < 0.01).
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relaxin-2 may play important roles in osteosarcoma devel-
opment and metastasis, which is also consistent with
previous reports in other malignancies [9,14-16,18,19].
It has found by Binder et al. [17] relaxin-2 concentra-
tions in cancer patients were significantly higher than in
a control population of healthy blood donors and pa-
tients with various other diseases. There was a signifi-
cant difference between patients with metastases and
those without, irrespective of their hormonal status. Our
results demonstrate that relaxin-2 serum concentrationsFigure 6 Tumor growth inhibition and prevention of metastasis and a
anti- relaxin-2 mAb at 100 ug weekly i.p for 42 d. inhibited primary tumor g
B, treatment with anti- relaxin-2 mAb at 100 ug weekly i.p for 42 d. promo
controls (n = 6; *P <0.01). C, inhibition of tumor angiogenesis by anti- relaxi
anti- relaxin-2 mAb–treated tumor was 0.57 ± 0.22%, which was significantl
cells transfected with Relaxin-2 siRNA (1 × 105 cells/100 uL in PBS) were inje
of tumor cells to lung after 2 weeks. The number of macroscopic tumor no
mouse versus 62.4 ± 7.4 nodules in the controls (n = 5 mice/group). One w
micro-metastasis in the lung of mice. *, P < 0.05.in a population of osteosarcoma patients yielded signifi-
cantly higher relaxin-2 concentrations than in a control
group of healthy blood donors. relaxin-2 concentrations
were elevated especially in patients with high clinical
stage and the status of hematogenous metastasis.
We therefore suggested that the expression of relaxin-2
mRNA in osteosarcoma tissues or relaxin-2 serum con-
centrations in a population of osteosarcoma patients may
serve as a new prognostic predictor for osteosarcoma.
Relaxin-2 may be the better target gene for treatment of
osteosarcoma.ngiogenesis formation by relaxin-2 inhibition. A, treatment with
rowth by 73 ± 6% compared with controls (n = 6; *P <0.01).
tes apoptosis in primary tumor cells by 8.2 ± 1.2% compared with
n-2 mAb treatment as measured by MVD. The vascular density of the
y lower than the controls 1.84 ± 0.26%.( n = 6). *, P < 0.01. D, MG-63
cted into the tail vein of SCID mice, followed by analysis of settlement
dules in Relaxin-2 siRNA–treated mice was 9.46 ± 1.8 lung nodules per
ay ANOVA analysis was performed to compare the number of
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http://www.cancerci.com/content/13/1/59It has recently found adenoviral-mediated delivery of
prorelaxin-2 gene increases the invasiveness of canine
breast cancer cells [16]. The lentiviral delivery of
relaxin-2 into PC-3 prostate cancer cells increases xeno-
graft tumor growth [15]. It was shown that relaxin-2 is a
direct downstream target of R273H p53 mutation in
prostate carcinoma cells [23], and relaxin expression is
up-regulated by androgen withdrawal in vitro and
in vivo [24]. Relaxin is also a potent stimulator of
osteoclastogenesis from hematopoietic precursors and
regulates the activity of mature osteoclasts [22], they did
not investigate whether relaxin has a potent effect on
osteoblasts.
MG-63 is the osteoblast, it has the osteoblast-like
features. Relaxin-2 was overexpressed in the MG-63
cells. In the present study, we investigate whether
relaxin-2 has a potent effect on MG-63 cells. To investi-
gate the potential of relaxin as an effective therapeutic
target for osteosarcoma gene therapy, we employed
RNA interference to knockdown the endogenous relaxin
expression in osteosarcoma cells, which showed that relaxin
downregulation could inhibit the proliferation capacity of
osteosarcoma cells. Moreover, relaxin downregulation
could induce apoptosis enhancement in osteosarcoma
cells. The results indicates that transfection might, to a
large degree, inhibit proliferation by inducing apoptosis in
osteosarcoma cells in vitro.
Previous studies have shown that knockdown of
relaxin-2 inhibited invasion and angiogenesis in cancer
cells in vitro [15,20]. In this study, we show that relaxin-
2 suppression by siRNA inhibited MG-63 cell migration
by migration assay. Relaxin was also shown to induce
vascular endothelial growth factor and procollagenase
expression in human endometrial cells and to stimulate
blood vessel formation in the primate endometrium
[25,26]. We show here that suppression of relaxin-2
gene reduces the endothelial tube formation of HUVEC
formation or capillary-like structures in HMECs. Thus,
relaxin-2 inhibition may act anti-angiogenic by a direct
effect on endothelial cells. These data provide evidence
that the relaxin-2 gene may be associated with prolifera-
tion, angiogenesis, invasion, and metastatic spread of
cancerous cells during progression of human osteosar-
coma in vitro.
It has shown above inhibition of relaxin-2 involved in
the growth, invasion, metastasis, and angiogenesis of
human osteosarcoma cells in vitro. We then studied the
effect of inhibition of relaxin-2 on osteosarcoma cells
in vivo mice modes. In this report, we demonstrate that
relaxin-2 suppression by anti- relaxin-2 mAb can greatly
inhibit the expression of relaxin-2 protein and suppress
the tumorigenic phenotype of MG-63 cells inoculated s.c.
in nude mice. When injected subcutaneously in nude
mice, all xenograft tumours derived from anti- relaxin-2mAb treated MG-63 tumors contained reduced or almost
undetectable levels of relaxin-2 protein when compared
with the control tumour tissues. Additionally, we showed
that the suppression of relaxin led to a significant increase
in cancer cell apoptosis.
Additional functions of relaxin-2, such as stimulation of
angiogenesis [15], might have also contributed to cancer
growth. In the present study, inhibit expression of relaxin-
2 by anti- relaxin-2 mAb was observed significant de-
creases in the expression of CD31. It reduced the MG-63
tumor vasculature, the new blood vessel formation was
significantly reduced in MG-63 tumor by anti- relaxin-2
mAb in the intervention model (80% inhibition), which
suggested that relaxin-2 blockage inhibits tumor growth
by in part inhibition of angiogenesis.
Osteosarcoma is characterized by a high propensity for
metastasis, especially in lung, which is the main cause of
death [2]. In vitro assays showed that relaxin-2 siRNA
treatment was indeed able to reduce significantly tumor
invasiveness. To investigate whether the relaxin-2 knock-
down can reduce the metastatic burden in MG-63 tumor,
MG-63/ relaxin-2 siRNA cells were injected to the mice
by tail. Mice with MG-63/ relaxin-2 siRNA cells were
sacrificed on the same day of tumor injection (14 days),
lungs were harvested and lung sections were examined for
cancer cell micrometastasis. The results showed the num-
ber of macroscopic tumor nodules in relaxin-2 siRNA-
treated mice was significantly decreased, and the effects
did reach statistical significance. This result is in contrast
with the findings of the in vitro assays, in which relaxin-2
inhibition was indeed able to inhibit invasion
In summary, our data demonstrated that relaxin −2
was overexpressed in osteosarcoma tissues and patients’.
Relaxin-2 mRNA and serum relaxin-2 were significantly
higher in advanced stage cancer and hematogenous
metastasis cancer. Downregulation of relaxin-2 by
siRNA or anti- relaxin-2 mAb on MG-63 effectively
suppressed tumor growth in vitro or vivo through in-
creased apoptosis and decreased proliferation of MG-63
cancer cells. Furthermore, the suppression of relaxin-2
significantly reduced invasion, lung metastasis, and
angiogenesis in vitro or vivo. We therefore suggested
that relaxin-2 may be as a potential therapeutic targets
for osteosarcoma treatment. However, the mechanisms
of relaxin-2 effects in osteosarcoma cells remain to be
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